REPRODIVAC – next-generation vaccines and diagnostics to prevent livestock reproductive diseases of worldwide impact
The REPRODIVAC project will develop next-generation vaccines and diagnostics to prevent and control infectious reproductive diseases of livestock of worldwide impact.
It will also develop improved vaccines and diagnostics for endemic and zoonotic reproductive pathogens of livestock to strengthen the profitability of food animal systems, improve animal welfare, reduce antimicrobial usage in farming and protect public health, with a ‘One Health’ perspective.
REPRODIVAC revolves around the following four main objectives:
- To genetically engineer a rationally attenuated B. suis vaccine and develop improved differential diagnostic tests to aid porcine brucellosis surveillance programs.
- To develop novel viral vectored vaccines designed to elicit antibodies that broadly neutralise PRRSV and an immunoassay to better measure PRRSV neutralising antibodies.
- To produce recombinant proteins to facilitate the identification and prioritisation of DIVA vaccine candidate Ags for Q fever and OEA, and companion diagnostic test.
- To refine the manufacture of a recently developed C. abortus subcellular chlamydial outer membrane complex (COMC) vaccine and its evaluation for commercialisation, and to produce a companion molecular diagnostic test.
- ENEA – Agenzia Nazionale per le Nuove Tecnologie (Coordinator)
- Moredun Research Institute
- University of Veterinary Medicine Vienna
- Wageningen University & Research
- Agenzia Nazionale per le Nuove tecnologie, l’Energia e lo Sviluppo Economico Sostenibile
- University of Lleida
- Consorci Centre D’estudis Porcins
- Ceva Animal Health
- Centro De Investigacion Y Tecnologia Agroalimentaria De Aragón
- University of Navarra
- University of Murcia
- École Polytechnique Fédérale de Lausanne
- Grup de Sanejament Porcí
- CZ Veterinaria S.A.
- Global DX Ltd